SOURCE: CEGEDIM

October 25, 2007 13:24 ET

CEGEDIM : First-half 2007 results

PARIS--(Marketwire - October 25, 2007) - CEGEDIM SUCCESSFULLY MANAGING ITS EXTERNAL GROWTH

Paris, 26 October 2007 - CEGEDIM, the European leader in CRM solutions and marketing studies for the pharmaceutical industry, generated an operational margin at 13%, in line with the first-half 2006 operational margin.

+-------------------------+------------+------------+-------+
|                         |  30/06/2007|  30/06/2006|       |
+-------------------------+------------+------------+-------+
|In thousands of euros    |         Net|         Net|  Var %|
+-------------------------+------------+------------+-------+
|Turnover                 |     323,416|     257,118|    26%|
+-------------------------+------------+------------+-------+
|Ordinary operating profit|      42,450|      33,421|    27%|
+-------------------------+------------+------------+-------+
|Ordinary operating margin|       13.1%|       13.0%|       |
+-------------------------+------------+------------+-------+
|Net cost of financial    |     -14,772|      -2,280|   548%|
|liabilities              |            |            |       |
+-------------------------+------------+------------+-------+
|Tax charge               |      -9,545|     -10,137|    -6%|
+-------------------------+------------+------------+-------+
|Share of profit/loss from|        -175|         -17|   929%|
|affiliated companies     |            |            |       |
+-------------------------+------------+------------+-------+
|After-tax profit/loss    |        -131|      -1,801|   -93%|
|from businesses held for |            |            |       |
|sale                     |            |            |       |
+-------------------------+------------+------------+-------+
|Net consolidated profit  |      17,827|      19,186|    -7%|
+-------------------------+------------+------------+-------+
|Group share              |      17,755|      19,105|    -7%|
+-------------------------+------------+------------+-------+
|Minority interests       |          72|          81|   -11%|
+-------------------------+------------+------------+-------+
|Earning per share (in    |         1.9|         2.1|       |
|euros)                   |            |            |       |
+-------------------------+------------+------------+-------+
+-------------------------+-------------------+---------------+
|In thousands of euros    |  Turnover 30/06/07|  EBIT 30/06/07|
+-------------------------+-------------------+---------------+
|CRM and strategic data   |            170,847|         26,515|
+-------------------------+-------------------+---------------+
|Healthcare professionals |             71,675|          9,890|
+-------------------------+-------------------+---------------+
|Healthcare insurance     |             40,587|          2,305|
|services                 |                   |               |
+-------------------------+-------------------+---------------+
|Healthcare and strategic |            283,109|         38,710|
|data                     |                   |               |
+-------------------------+-------------------+---------------+
|Technology and services  |             40,307|          3,740|
+-------------------------+-------------------+---------------+
|Total Cegedim            |            323,416|         42,450|
+-------------------------+-------------------+---------------+
+-------------------------+-------------------+---------------+

+-------------------------+------------------+-------------------+
|In thousands of euros    |  EBIT/TO 30/06/07|  Turnover 30/06/06|
+-------------------------+------------------+-------------------+
|CRM and strategic data   |             15.5%|            119,717|
+-------------------------+------------------+-------------------+
|Healthcare professionals |             13.8%|             64,130|
+-------------------------+------------------+-------------------+
|Healthcare insurance     |              5.7%|             39,409|
|services                 |                  |                   |
+-------------------------+------------------+-------------------+
|Healthcare and strategic |             13.7%|            223,256|
|data                     |                  |                   |
+-------------------------+------------------+-------------------+
|Technology and services  |              9.3%|             33,862|
+-------------------------+------------------+-------------------+
|Total Cegedim            |             13.1%|            257,118|
+-------------------------+------------------+-------------------+
+-------------------------+------------------+-------------------+

+-------------------------+---------------+------------------+
|In thousands of euros    |  EBIT 30/06/06|  EBIT/TO 30/06/06|
+-------------------------+---------------+------------------+
|CRM and strategic data   |         20,056|             16.8%|
+-------------------------+---------------+------------------+
|Healthcare professionals |          7,569|             11.8%|
+-------------------------+---------------+------------------+
|Healthcare insurance     |          3,905|              9.9%|
|services                 |               |                  |
+-------------------------+---------------+------------------+
|Healthcare and strategic |         31,530|             14.1%|
|data                     |               |                  |
+-------------------------+---------------+------------------+
|Technology and services  |          1,891|              5.6%|
+-------------------------+---------------+------------------+
|Total Cegedim            |         33,421|             13.0%|
+-------------------------+---------------+------------------+
+-------------------------+---------------+------------------+
The Dendrite acquisition was the highlight of the first half of 2007. Dendrite contributed EUR 45 million in consolidated revenues from 9 May 2007. In accordance with IFRS, the activities held for sale to Tessi are presented separately in the consolidated financial statements. Impact on sales is around EUR 10 million. Excluding the Tessi impact, consolidated sales came to EUR 333 million.

The "CRM and strategic data" sector, whose businesses cater to pharmaceutical companies, posted a strong operating margin close to 16%. French businesses confirm their maturity, while margins were bolstered by substantial international development.

The Group also generated substantial growth in H1 sales and operating margins in the "Healthcare professionals" businesses. The two-point increase in operating margin compared with H1 2006 was mainly fuelled by a sharp drop in the operating costs of Cegedim's French medical software activities, which have generated losses for years but are on the road to becoming profitable.

"Insurance services" sector sales rose a steady 3% year on year. Operating margin for the first half of 2007 was 5.7%, dipping temporarily due to the launch of a promising new business: I-santé.

The "Technology and services" division's operating margin rose substantially, particularly due to the fine performance of Cegelease.

Together, these factors produced an operating profit of EUR 42 million.

The net profit of businesses held for sale to Tessi represented a loss to the company of EUR 131,000, giving Cegedim Group a consolidated net profit of EUR 17.8 million.

2007 outlook

Cegedim Group is still confirming its full-year sales forecast, expecting overall growth of around 7% for the year (Dendrite's impacts not included).

Ownership of activities sold was effectively transferred to Tessi on 2 July 2007.

About CEGEDIM:

CEGEDIM has been developing exclusive databases and high value added software solutions since 1969.

Established as the world's leading CRM provider for the life sciences industry with its Cegedim Dendrite business unit, CEGEDIM provides the world's largest pharmaceutical companies with vital support for successful Customer Relationship Management (CRM). Its Cegedim Strategic Data and Cegedim Customer Information business units are also dedicated to pharmaceutical companies and help them improve sales & marketing effectiveness thanks to the Group's strategic databases focused on the world drug market.

This expertise falls into the "Healthcare and strategic data" division of the CEGEDIM Group, which comprises the services specifically designed for pharmaceutical companies cited above and specific solutions dedicated to healthcare professionals (notably physicians and pharmacists in Europe) and health insurance providers.

The "Technologies and services" division capitalizes on the Group's technical skills in order to provide specific solutions to clients of various sectors, essentially in France.

Cegedim generated turnover of EUR 541 million in 2006. Including Dendrite, the combined Group's pro forma 2006 revenue would amount to EUR 877 million for a workforce of 7,500 and operations in more than 80 countries. To learn more, please see our website: www.cegedim.com

Listed on Eurolist by Euronext Paris - Compartment B ISIN FR0000053506 - Reuters CGDM.PA - Bloomberg CGM

+-------------------------+--------------------+
|Media inquiries          |Investor relations  |
+-------------------------+--------------------+
|CEGEDIM                  |             CEGEDIM|
+-------------------------+--------------------+
|Aude Balleydier          |   Sandrine Debroise|
+-------------------------+--------------------+
|Media Relations          |Chief Financial     |
|                         |Officer             |
+-------------------------+--------------------+
|Tél. : +33 1 49 09 68 81 |                    |
+-------------------------+--------------------+
|aude.balleydier@cegedim.f|     Antoine Alazard|
|r                        |                    |
+-------------------------+--------------------+
|                         |Special Advisor     |

|                         |Financial Department|
+-------------------------+--------------------+
|VP COMMUNICATION         |                    |
+-------------------------+--------------------+
|Coralie Voigt            |   Annelise Falandry|
+-------------------------+--------------------+
|Press Officer            |In charge of        |
|                         |financial           |
|                         |communication       |
+-------------------------+--------------------+
|Tél. : +33 1 40 22 04 01 |Tél. : +33 1 49 09  |
|                         |22 00               |
+-------------------------+--------------------+
|cvoigt@vp-communication.c|investor.relations@c|
|om                       |egedim.fr           |
+-------------------------+--------------------+
This information is provided by CompanynewsGroup

Contact Information